Risk factors associated hyphema after intravitreal injection of bevacizumab before trabeculectomy for neovascular glaucoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20160826002

Enrollment

Registered

2016-08-26

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular glaucoma uncontrolled IOP NVG hyphema intravireal avastin bevacizumab injection trabeculectomy NVI

Interventions

trabeculectomy less than 7 days after intravitreal bevacizumab injection,trabeculectomy between 7&#45

14 days after intravitreal bevacizumab injection

Treatment,Treatment

less than 7 days ,7&#45

14 days

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Neovascular glaucoma patient at least 18 years old IOP >21mmHg with full medications multiple medications or side effects with medications

Exclusion criteria

Exclusion criteria: CVS or CNS disease or poor health status previous eye surgery currenly taking anti platelet or anticoagulant unable to stop 7 days before surgery hyphema before surgery VA= no light perception

Design outcomes

Primary

Measure	Time frame
risk factor of post trabeculectomy hyphema after intravitreal bevacizumab injection none risk factors	—

Secondary

Measure	Time frame
short-term outcome of trabeculectomy in NVG none outcome	—

Countries

thailand

Contacts

Public ContactThidarat Leeungurasatien

chiangmai university hospital

tleeungu@gmail.com08825223624

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026